Wendye Robbins
Director/Board Member chez RAPT THERAPEUTICS, INC.
Fortune : 246 950 $ au 31/03/2024
Profil
Wendye R.
Robbins is the founder of Labrys Biologics, Inc. (2012), NeurogesX, Inc. (2000), Limerick BioPharma, Inc. (2006), and Blade Therapeutics, Inc. (2015).
She currently holds the position of President & Chief Executive Officer at Blade Therapeutics, Inc. and Chief Executive Officer at Incendia Therapeutics, Inc. She also serves as a Director at Theraclone Sciences, Inc., Independent Director at Rapt Therapeutics, Inc., Director at California Life Sciences Association, and Assistant Professor at Stanford University.
Dr. Robbins has a doctorate degree from Drexel University, an undergraduate degree from Haas School of Business, and a graduate degree from Perelman School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RAPT THERAPEUTICS, INC.
0,08% | 28/03/2024 | 27 500 ( 0,08% ) | 246 950 $ | 31/03/2024 |
Postes actifs de Wendye Robbins
| Sociétés | Poste | Début |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Director/Board Member | 22/10/2019 |
| Stanford University | Corporate Officer/Principal | 01/01/2004 |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Director/Board Member | - |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Director/Board Member | 04/03/2019 |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
Incendia Therapeutics, Inc.
 Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Chief Executive Officer | 07/11/2023 |
Anciens postes connus de Wendye Robbins
| Sociétés | Poste | Fin |
|---|---|---|
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Founder | 01/12/2022 |
Limerick BioPharma, Inc.
 Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Founder | 01/12/2011 |
| NEUROGESX, INC | Founder | 01/01/2003 |
| ░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Formation de Wendye Robbins
| Drexel University | Doctorate Degree |
| Haas School of Business | Undergraduate Degree |
| Perelman School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RAPT THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
Labrys Biologics, Inc.
 Labrys Biologics, Inc. BiotechnologyHealth Technology Labrys Biologics, Inc. provides biotechnology services. It is a venture-financed development stage biotechnology company, which focuses on treatments for chronic migraine. The company was founded by Corey S. Goodman in 2012 and is headquartered in San Francisco, CA. | Health Technology |
NeurogesX, Inc.
 NeurogesX, Inc. Pharmaceuticals: MajorHealth Technology NeurogesX, Inc. developed and commercialized novel pain management therapies. The company was founded by Wendye R. Robbins on May 28, 1998 and was headquartered in San Mateo, CA. | Health Technology |
Limerick BioPharma, Inc.
Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Health Technology |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Commercial Services |
Incendia Therapeutics, Inc.
Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Health Technology |
